JP2011050389A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011050389A5 JP2011050389A5 JP2010228397A JP2010228397A JP2011050389A5 JP 2011050389 A5 JP2011050389 A5 JP 2011050389A5 JP 2010228397 A JP2010228397 A JP 2010228397A JP 2010228397 A JP2010228397 A JP 2010228397A JP 2011050389 A5 JP2011050389 A5 JP 2011050389A5
- Authority
- JP
- Japan
- Prior art keywords
- mammal
- test sample
- polypeptide
- sample
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000523 sample Substances 0.000 claims 21
- 241000124008 Mammalia Species 0.000 claims 10
- 230000014509 gene expression Effects 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 8
- 210000001519 tissues Anatomy 0.000 claims 8
- 102000004965 antibodies Human genes 0.000 claims 7
- 108090001123 antibodies Proteins 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 6
- 230000002757 inflammatory Effects 0.000 claims 6
- 206010021425 Immune system disease Diseases 0.000 claims 4
- 208000008425 Protein Deficiency Diseases 0.000 claims 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 4
- 230000001404 mediated Effects 0.000 claims 4
- 210000004404 Adrenal Cortex Anatomy 0.000 claims 2
- 208000009094 Anemia, Hemolytic, Autoimmune Diseases 0.000 claims 2
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 2
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000007924 IgA Deficiency Diseases 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010028417 Myasthenia gravis Diseases 0.000 claims 2
- 206010025310 Other lymphomas Diseases 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 206010039915 Selective IgA immunodeficiency Diseases 0.000 claims 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 150000004676 glycans Polymers 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 201000007156 immunoglobulin alpha deficiency Diseases 0.000 claims 2
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 2
- 201000008383 nephritis Diseases 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 150000004804 polysaccharides Polymers 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 230000001052 transient Effects 0.000 claims 2
- 241000972773 Aulopiformes Species 0.000 claims 1
- 229960000633 Dextran Sulfate Drugs 0.000 claims 1
- 206010027665 Immune disorder Diseases 0.000 claims 1
- 108020004999 Messenger RNA Proteins 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J Tetrasodium pyrophosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 claims 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 229920002106 messenger RNA Polymers 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 235000019515 salmon Nutrition 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- 229940048086 sodium pyrophosphate Drugs 0.000 claims 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 claims 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims 1
- 239000011778 trisodium citrate Substances 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
Claims (20)
- 哺乳動物の炎症性免疫応答を検出する方法であって、（ａ）哺乳動物から採取した組織細胞の試験試料中と、（ｂ）同じ細胞型の既知の正常組織細胞のコントロール試料中における、配列番号：２９の配列に対して少なくとも９０％の配列同一性を有するＰＲＯ７ポリペプチドをコード化する遺伝子発現の核酸レベルを検出することを含み、コントロール試料と比較して試験試料中における前記遺伝子の差次的な発現が、試験組織細胞が得られた哺乳動物における炎症性免疫応答の存在を示す方法。
- 炎症性免疫応答がＢ細胞媒介免疫応答である、請求項１に記載の方法。
- 哺乳動物の免疫関連疾患を検出する方法であって、（ａ）哺乳動物から採取した組織細胞の試験試料中と、（ｂ）同じ細胞型の既知の正常組織細胞のコントロール試料中における、配列番号：２９の配列に対して少なくとも９０％の配列同一性を有するＰＲＯ７ポリペプチドをコード化する遺伝子発現の核酸レベルを検出することを含み、コントロール試料と比較して試験試料中における前記遺伝子の差次的な発現が、試験組織細胞が得られた哺乳動物における免疫関連疾患の存在を示す方法。
- 免疫関連疾患がＢ細胞媒介免疫疾患である、請求項３に記載の方法。
- Ｂ細胞媒介免疫疾患が、全身性エリテマトーデス、Ｘ染色体連鎖の乳児性低ガンマグロブリン症、多糖体抗原無応答性、選択性ＩｇＡ欠乏、選択性ＩｇＭ欠乏、ＩｇＧサブクラスの選択性欠乏、高ＩｇＭを伴う免疫不全、一過性乳児期低ガンマグロブリン症、バーキットリンパ腫、中間リンパ腫、濾胞性リンパ腫、２型過敏症、リウマチ様関節炎、自己免疫性溶血性貧血、重症筋無力症、低副腎皮質、糸球体腎炎及び強直性脊椎炎である、請求項４に記載の方法。
- 核酸レベルは、試験試料及び正常試料から得られた核酸の、配列番号：２９の配列に対して少なくとも９０％の配列同一性を有するＰＲＯ７ポリペプチドをコード化する核酸に特異的な一又は複数のプローブへのハイブリダイゼーションにより測定する、請求項１又は３の方法。
- ハイブリダイゼーションが緊縮性条件下で行われる、請求項６に記載の方法。
- 緊縮性条件は、５０％ホルムアミド、５×ＳＳＣ、５０ｍＭのリン酸ナトリウム（ｐＨ６．８）、０．１％のピロリン酸ナトリウム、５×デンハード液、超音波処理サケ精子ＤＮＡ（５０μｇ／ｍｌ）、０．１％ＳＤＳ、及び１０％のデキストラン硫酸と、４２℃における０．２ｘＳＳＣ（塩化ナトリウム／クエン酸ナトリウム）中の洗浄及び５５℃での５０％ホルムアミド、ついで５５℃におけるＥＤＴＡを含む０．１×ＳＳＣを用いる、請求項７に記載の方法。
- 試験試料及び正常試料から得られた核酸はｍＲＮＡである、請求項１又は３に記載の方法。
- 試験試料及び正常試料から得られた核酸がマイクロアレイ上に置かれる、請求項９に記載の方法。
- 哺乳動物の炎症性免疫応答を検出する方法であって、正常試料と比較した試験試料中における、配列番号：２９の配列に対して少なくとも９０％の配列同一性を有するＰＲＯ７ポリペプチドの発現レベルを検出することを含み、試験試料中における前記ポリペプチドの差次的な発現が、試験組織細胞が得られた哺乳動物における炎症性免疫応答の存在を示す方法。
- 炎症性免疫応答がＢ細胞媒介免疫応答である、請求項１１に記載の方法。
- 哺乳動物の免疫関連疾患を検出する方法であって、正常試料と比較した試験試料中における、配列番号：２９の配列に対して少なくとも９０％の配列同一性を有するＰＲＯ７ポリペプチドの発現レベルを検出することを含み、試験試料中における前記ポリペプチドの差次的な発現が、試験組織細胞が得られた哺乳動物における免疫関連疾患の存在を示す方法。
- 免疫関連疾患がＢ細胞媒介免疫疾患である、請求項１３に記載の方法。
- Ｂ細胞媒介免疫疾患が、全身性エリテマトーデス、Ｘ染色体連鎖の乳児性低ガンマグロブリン症、多糖体抗原無応答性、選択性ＩｇＡ欠乏、選択性ＩｇＭ欠乏、ＩｇＧサブクラスの選択性欠乏、高ＩｇＭを伴う免疫不全、一過性乳児期低ガンマグロブリン症、バーキットリンパ腫、中間リンパ腫、濾胞性リンパ腫、２型過敏症、リウマチ様関節炎、自己免疫性溶血性貧血、重症筋無力症、低副腎皮質、糸球体腎炎及び強直性脊椎炎である、請求項１４に記載の方法。
- 発現がＰＲＯ７ポリペプチドに特異的な抗体を用いて検出される、請求項１１又は１３に記載の方法。
- 前記抗体がモノクローナル抗体である、請求項１６に記載の方法。
- 前記抗体がヒト化抗体である、請求項１７に記載の方法。
- 前記抗体が抗体断片である、請求項１７に記載の方法。
- 前記抗体が標識されている、請求項１７に記載の方法。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41139202P | 2002-09-16 | 2002-09-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004536566A Division JP2006515165A (ja) | 2002-09-16 | 2003-09-15 | 免疫関連疾患の治療のための新規組成物と方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011086366A Division JP2011172580A (ja) | 2002-09-16 | 2011-04-08 | 免疫関連疾患の治療のための新規組成物と方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011050389A JP2011050389A (ja) | 2011-03-17 |
| JP2011050389A5 true JP2011050389A5 (ja) | 2011-05-26 |
Family
ID=31994259
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004536566A Withdrawn JP2006515165A (ja) | 2002-09-16 | 2003-09-15 | 免疫関連疾患の治療のための新規組成物と方法 |
| JP2010228397A Pending JP2011050389A (ja) | 2002-09-16 | 2010-10-08 | 免疫関連疾患の治療のための新規組成物と方法 |
| JP2011086366A Withdrawn JP2011172580A (ja) | 2002-09-16 | 2011-04-08 | 免疫関連疾患の治療のための新規組成物と方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004536566A Withdrawn JP2006515165A (ja) | 2002-09-16 | 2003-09-15 | 免疫関連疾患の治療のための新規組成物と方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011086366A Withdrawn JP2011172580A (ja) | 2002-09-16 | 2011-04-08 | 免疫関連疾患の治療のための新規組成物と方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20070010434A1 (ja) |
| EP (2) | EP1578364A4 (ja) |
| JP (3) | JP2006515165A (ja) |
| AU (2) | AU2003291625B2 (ja) |
| CA (1) | CA2498274A1 (ja) |
| WO (1) | WO2004024097A2 (ja) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040072268A1 (en) * | 2002-08-05 | 2004-04-15 | Ramin Shiekhattar | Methods for regulating BRCA1-BRCA2-containing complex activity |
| AU2002950779A0 (en) * | 2002-08-15 | 2002-09-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | A method of immunomodulation |
| US20050037946A1 (en) * | 2003-01-13 | 2005-02-17 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419 |
| EP1460088A1 (en) | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
| US20070123455A1 (en) * | 2003-04-04 | 2007-05-31 | Joel Palefsky | Immunomodulatory agents for treatment of inflammatory diseases |
| US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
| US20050272067A1 (en) * | 2004-03-10 | 2005-12-08 | Macina Roberto A | Compositions, splice variants and methods relating to cancer specific genes and proteins |
| EP2270160A1 (en) * | 2004-06-14 | 2011-01-05 | Galapagos N.V. | Methods for identification, and compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2006097335A1 (en) * | 2005-03-18 | 2006-09-21 | Universität Zürich | A new element of the wg/wnt signaling pathway |
| JP4742205B2 (ja) * | 2005-03-23 | 2011-08-10 | 国立大学法人大阪大学 | Ｈｉｖ転写制御因子 |
| FI20065035A (fi) * | 2006-01-19 | 2007-07-20 | Polysackaridforskning I Uppsal | Olennaisesti puhdas entsyymi |
| WO2008104803A2 (en) | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
| NZ583429A (en) * | 2007-08-24 | 2012-08-31 | Mylexa Pty Ltd | Peptides and proteins capable of inhibiting and/or preventing mast cell activation |
| JP2009055838A (ja) * | 2007-08-31 | 2009-03-19 | Nipro Corp | 融合タンパク質、該融合タンパク質に関連する遺伝子、ベクター、形質転換体及び抗炎症性医薬組成物 |
| BRPI0909048A2 (pt) | 2008-03-13 | 2015-11-24 | Biotest Ag | composição farmacêutica, e, método de tratamento de uma doença autoimune |
| BRPI0909179A2 (pt) | 2008-03-13 | 2015-08-25 | Biotest Ag | Composição farmacêutica, e, método de tratamento de uma doença autoimune. |
| MX2010010026A (es) | 2008-03-13 | 2011-03-21 | Biotest Ag | Agente para tratar enfermedad. |
| PT2659904E (pt) | 2008-06-26 | 2016-01-22 | Orphazyme Aps | Uso da hsp70 como um regulador da atividade enzimática |
| WO2014042828A2 (en) | 2012-09-17 | 2014-03-20 | Cedars-Sinai Medical Center | Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia |
| US10132814B2 (en) | 2014-10-09 | 2018-11-20 | Cedars-Sinai Medical Center | Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease |
| US11693009B2 (en) | 2009-02-11 | 2023-07-04 | Cedars-Sinai Medical Center | Methods for detecting post-infectious irritable bowel syndrome |
| WO2010141999A1 (en) * | 2009-06-12 | 2010-12-16 | The University Of Queensland | Agents and methods for diagnosing and treating ankylosing spondylitis |
| GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
| BR112013013143A2 (pt) | 2010-11-30 | 2016-08-23 | Orphazyme Aps | composto, e, método de tratamento de uma doença de armazenagem lisossômica |
| BR112016007474A2 (pt) | 2013-10-09 | 2017-09-12 | Cedars Sinai Medical Center | diagnóstico e tratamento de síndrome do intestino irritável e doença inflamatória intestinal |
| LT3055331T (lt) | 2013-10-11 | 2021-03-25 | Oxford Bio Therapeutics Limited | Konjuguoti antikūnai prieš ly75, skirti vėžio gydymui |
| CA2961097C (en) | 2014-09-15 | 2023-09-26 | Orphazyme Aps | Extended-release pharmaceutical formulation comprising arimoclomol |
| CN108064166A (zh) * | 2014-10-23 | 2018-05-22 | 戊瑞治疗有限公司 | Slamf1拮抗剂及其用途 |
| GEP20227447B (en) | 2015-08-07 | 2022-12-12 | Alx Oncology Inc | Constructs having sirp-alpha domain or variant thereof |
| EP3442530A1 (en) | 2016-04-13 | 2019-02-20 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
| LT3448382T (lt) | 2016-04-29 | 2021-04-12 | Orphazyme A/S | Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti |
| AU2017318610B2 (en) | 2016-09-02 | 2021-12-09 | The Board Of Trustees Of The University Of Illinois | KIF13B-derived peptide and method of inhibiting Angiogenesis |
| CA3071193A1 (en) | 2017-07-26 | 2019-01-31 | Forty Seven, Inc. | Anti-sirp-alpha antibodies and related methods |
| JP2022534212A (ja) | 2019-05-31 | 2022-07-28 | エーエルエックス オンコロジー インコーポレイテッド | 免疫チェックポイント阻害剤と組み合わせてｓｉｒｐアルファｆｃ融合によりがんを治療する方法 |
| WO2022106614A1 (en) | 2020-11-19 | 2022-05-27 | Orphazyme A/S | Processes for preparing arimoclomol citrate and intermediates thereof |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4943529A (en) | 1982-05-19 | 1990-07-24 | Gist-Brocades Nv | Kluyveromyces as a host strain |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| AU3145184A (en) | 1983-08-16 | 1985-02-21 | Zymogenetics Inc. | High expression of foreign genes in schizosaccharomyces pombe |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| AU603768B2 (en) * | 1985-07-04 | 1990-11-29 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946783A (en) | 1987-01-30 | 1990-08-07 | President And Fellows Of Harvard College | Periplasmic protease mutants of Escherichia coli |
| US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
| IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
| GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| KR0154872B1 (ko) | 1987-12-21 | 1998-10-15 | 로버트 에이. 아미테이지 | 발아하는 식물종자의 아크로박테리움 매개된 형질전환 |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| ATE144281T1 (de) | 1989-04-28 | 1996-11-15 | Rhein Biotech Proz & Prod Gmbh | Hefezellen der gattung-schwanniomyces |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| EP0585257A4 (en) * | 1991-03-28 | 1995-02-22 | Univ Minnesota | DNA AND AMINO ACID SEQUENCE SPECIFIC TO NATURAL K KILLER CELLS. |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| DE69326937T2 (de) | 1993-03-24 | 2000-12-28 | Berlex Biosciences Richmond | Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AU2582897A (en) | 1996-03-15 | 1997-10-01 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
| US5846780A (en) * | 1996-10-04 | 1998-12-08 | Millennium Pharmaceuticals, Inc. | Murine RATH gene |
| WO1999013075A2 (en) * | 1997-09-08 | 1999-03-18 | Princeton University | Human genes regulated by human cytomegalovirus and interferon |
| WO2000029448A2 (en) * | 1998-11-17 | 2000-05-25 | Sagami Chemical Research Center | Human proteins having hydrophobic domains and dnas encoding these proteins |
| AU4057600A (en) * | 1999-03-31 | 2000-10-16 | Rosetta Inpharmatics, Inc. | Methods for the identification of reporter and target molecules using comprehensive gene expression profiles |
| AU6230700A (en) * | 1999-07-21 | 2001-02-13 | Incyte Genomics, Inc. | Cell cycle and proliferation proteins |
| AU7680300A (en) * | 1999-08-18 | 2001-03-13 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Human dna sequences |
| US6395889B1 (en) * | 1999-09-09 | 2002-05-28 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding human protease homologs |
| AU1334101A (en) * | 1999-11-02 | 2001-05-14 | Human Genome Sciences, Inc. | 19 human secreted proteins |
| AU2001243142A1 (en) * | 2000-02-03 | 2001-08-14 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| AU2001260153B2 (en) * | 2000-03-24 | 2006-08-17 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the NKG2D receptor complex |
| EP1358347A2 (en) * | 2000-04-05 | 2003-11-05 | Incyte Genomics, Inc. | Genes expressed in foam cell differentiation |
| WO2001090304A2 (en) * | 2000-05-19 | 2001-11-29 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| AU2001264099A1 (en) * | 2000-06-13 | 2001-12-24 | University College Cardiff Consultants Ltd. | Zinc transporters |
| US6974667B2 (en) * | 2000-06-14 | 2005-12-13 | Gene Logic, Inc. | Gene expression profiles in liver cancer |
| CA2412626C (en) * | 2000-06-22 | 2013-10-22 | Amgen Inc. | Il-17 molecules and uses thereof |
| EP1317471A4 (en) * | 2000-08-18 | 2004-07-21 | Human Genome Sciences Inc | 21 HUMAN SECRETED PROTEINS |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| WO2002068579A2 (en) * | 2001-01-10 | 2002-09-06 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
-
2003
- 2003-09-15 WO PCT/US2003/029097 patent/WO2004024097A2/en active Application Filing
- 2003-09-15 AU AU2003291625A patent/AU2003291625B2/en not_active Ceased
- 2003-09-15 EP EP03768511A patent/EP1578364A4/en not_active Withdrawn
- 2003-09-15 EP EP11189800A patent/EP2444409A2/en not_active Withdrawn
- 2003-09-15 CA CA002498274A patent/CA2498274A1/en not_active Abandoned
- 2003-09-15 US US10/528,260 patent/US20070010434A1/en not_active Abandoned
- 2003-09-15 JP JP2004536566A patent/JP2006515165A/ja not_active Withdrawn
-
2008
- 2008-12-05 US US12/315,879 patent/US20090155263A1/en not_active Abandoned
-
2010
- 2010-01-07 AU AU2010200063A patent/AU2010200063B2/en not_active Ceased
- 2010-10-08 JP JP2010228397A patent/JP2011050389A/ja active Pending
- 2010-11-02 US US12/925,947 patent/US20110110938A1/en not_active Abandoned
-
2011
- 2011-04-08 JP JP2011086366A patent/JP2011172580A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011050389A5 (ja) | ||
| Colbert et al. | A yeast TFIIB-related factor involved in RNA polymerase III transcription. | |
| Beisser et al. | The R33 G protein-coupled receptor gene of rat cytomegalovirus plays an essential role in the pathogenesis of viral infection | |
| Balan et al. | The Candida albicans CDR3 gene codes for an opaque-phase ABC transporter | |
| JP5913547B2 (ja) | 診断および治療のための腫瘍関連抗原の同定 | |
| JP2012254093A5 (ja) | ||
| Sadhu et al. | A G-protein α subunit from asexual Candida albicans functions in the mating signal transduction pathway of Saccharomyces cerevisiae and is regulated by the al-α2 repressor | |
| Hasegawa et al. | Distinct roles for Khd1p in the localization and expression of bud-localized mRNAs in yeast | |
| JP2008301822A5 (ja) | ||
| JP2012115275A5 (ja) | ||
| US9127087B2 (en) | High affinity recombinant sea lamprey antibodies selected by a Yeast Surface Display platform | |
| JP2009519002A5 (ja) | ||
| Hsueh et al. | G protein signaling governing cell fate decisions involves opposing Gα subunits in Cryptococcus neoformans | |
| JP2009039107A5 (ja) | ||
| JP2010227106A5 (ja) | ||
| Yang et al. | Unraveling the molecular basis of temperature-dependent genetic regulation in Penicillium marneffei | |
| Hosseini et al. | In silico prediction of B and T cell epitopes based on NDV fusion protein for vaccine development against Newcastle disease virus | |
| US8586298B2 (en) | Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia | |
| US20230140801A1 (en) | Antibody capable of binding specifically to 5' to 3' exonuclease active domain of dna polymerase | |
| JP2010029191A5 (ja) | ||
| CN109313182A (zh) | 鱼变态反应的抗原 | |
| US20040062769A1 (en) | Identification of the domain of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) that mediates adhesion to chondroitin sulfate A | |
| JP2010035551A (ja) | シグレック１４遺伝子の多型に基づく対立遺伝子型の検出用試薬 | |
| JP6465655B2 (ja) | 発作障害及び運動障害に関連する遺伝子及びその変異 | |
| JP2021501601A5 (ja) |